文献速递淋巴瘤

国际预后指数、美国国家综合癌症网络IPI及年龄调整IPI在弥漫大B细胞淋巴瘤中的预后价值

[The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2018-01-01

该研究回顾性分析2003年1月至2012年12月南方医院311例初治弥漫大B细胞淋巴瘤患者,比较IPI、NCCN-IPI和aa-IPI的预后分层能力。结果显示,接受R-CHOP方案者NCCN-IPI分层能力优于IPI和aa-IPI;接受CHOP方案者aa-IPI预测预后优于IPI和NCCN-IPI。

要点

  • R-CHOP组NCCN-IPI对低危、中低危、中高危的5年OS分层优于IPI。
  • CHOP组aa-IPI和NCCN-IPI区分中低危与中高危的5年OS优于IPI。
  • ≤60岁患者中aa-IPI的C-index在CHOP组和R-CHOP组均最高。

核心结论

  • NCCN-IPI对接受R-CHOP方案治疗的DLBCL患者预后分层能力强于IPI和aa-IPI。
  • aa-IPI对接受不含利妥昔单抗的蒽环类化疗的较年轻DLBCL患者预后预测可能优于IPI和NCCN-IPI。

研究设计与样本

  • 回顾性分析2003年1月至2012年12月南方医院311例初治DLBCL患者资料。
  • 按治疗方案分为CHOP组128例和R-CHOP组183例。
  • 采用Harrell's C统计评价IPI、NCCN-IPI和aa-IPI的预后分层能力。

主要发现

  • CHOP组中,aa-IPI区分中低危与中高危的5年OS为71.0%对25.0%(P<0.001),NCCN-IPI为59.7%对26.8%(P<0.001),IPI为47.6%对36.6%(P=0.003)。
  • R-CHOP组中,NCCN-IPI低危、中低危、中高危患者的5年OS分别为96.0%、83.0%、66.5%(P=0.009)。
  • CHOP组IPI、NCCN-IPI、aa-IPI预测OS的C-index分别为0.546、0.667、0.698;R-CHOP组分别为0.611、0.654、0.695。
  • ≤60岁患者中,CHOP组IPI、NCCN-IPI、aa-IPI预测OS的C-index分别为0.534、0.675、0.698;R-CHOP组分别为0.584、0.648、0.695。

关键数值与推荐

  • CHOP组中低危与中高危5年OS:aa-IPI 71.0%对25.0%(P<0.001),NCCN-IPI 59.7%对26.8%(P<0.001),IPI 47.6%对36.6%(P=0.003)。
  • R-CHOP组NCCN-IPI低危、中低危、中高危5年OS分别为96.0%、83.0%、66.5%(P=0.009)。
  • CHOP组OS的C-index:IPI 0.546、NCCN-IPI 0.667、aa-IPI 0.698;R-CHOP组:IPI 0.611、NCCN-IPI 0.654、aa-IPI 0.695。
  • ≤60岁患者CHOP组OS的C-index:IPI 0.534、NCCN-IPI 0.675、aa-IPI 0.698;R-CHOP组:IPI 0.584、NCCN-IPI 0.648、aa-IPI 0.695。

临床怎么用

  • 对接受R-CHOP方案治疗的DLBCL患者,NCCN-IPI的预后分层能力优于IPI和aa-IPI。
  • 对接受不含利妥昔单抗的蒽环类化疗的较年轻DLBCL患者,aa-IPI的预后预测可能优于IPI和NCCN-IPI。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the prognostic value of the international prognostic index (IPI), the national comprehensive cancer network IPI(NCCN-IPI)and the age-adjusted IPI (aa-IPI) in diffuse large B cell lymphoma. Methods: A total of 311 patients with de novo diffuse large B-cell lymphoma (DLBCL) diagnosed from 2003 to 2012 in Nanfang hospital were included. All patients were divided into CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisone) and R-CHOP (rituximab, CHOP) groups. Survival analysis was compared among IPI, NCCN-IPI and aa-IPI models. Discrimination of three different prognostic models was assessed using the Harrell's C statistic. Results: A total of 311 patients were analyzed. Among them, 128 patients were treated with CHOP regimen and other 183 patients were treated with R-CHOP regimen. In CHOP groups, both NCCN-IPI (5-year OS: 59.7% vs 26.8%, P<0.001) and aa-IPI (5-year OS: 71.0% vs 25.0%, P<0.001) showed better risk stratification for low-intermediate and high-intermediate group than the IPI (5-year OS: 47.6% vs 36.6%, P=0.003). However, in the patients treated with R-CHOP, NCCN-IPI showed better risk stratification in low, low-intermediate, high-intermediate groups (5-year OS: 96.0% vs 83.0% vs 66.5%, P=0.009). According to the Harrell's C statistic, C-index of IPI, NCCN-IPI and aa-IPI for overall survival (OS) were 0.546, 0.667, 0.698 in CHOP group and 0.611,0.654, 0.695 in R-CHOP group respectively. In patients younger than 60 years old, C-index of IPI, NCCN-IPI and aa-IPI for OS were 0.534, 0.675, 0.698 in CHOP group and 0.584, 0.648, 0.695 in R-CHOP respectively. Conclusion: The NCCN-IPI is more powerful than IPI and aa-IPI in DLBCL patients receiving R-CHOP. aa-IPI is a preferable model in predicting prognosis than IPI and NCCN-IPI in anthracycline-based chemotherapy without rituximab. 目的: 比较IPI、美国国家综合癌症网络IPI(NCCN-IPI)及年龄调整的IPI(aa-IPI)三种预后分层模型在弥漫大B细胞淋巴瘤(DLBCL)患者中的预后分层能力。 方法: 回顾性分析2003年1月至2012年12月311例初治DLBCL患者资料,根据治疗方案将患者分为CHOP(环磷酰胺、多柔比星、长春新碱、泼尼松)方案及利妥昔单抗(R)-CHOP方案组,分别采用IPI、NCCN-IPI及aa-IPI对DLBCL患者进行危险度分层。采用Harrell’s C统计评价不同模型的预后分层能力。 结果: ①311例患者中接受CHOP方案治疗者128例,接受R-CHOP方案治疗者183例。②CHOP方案组患者的5年总生存(OS)率结果显示,aa-IPI(71.0%对25.0%,P<0.001)、NCCN-IPI(59.7%对26.8%,P<0.001)和IPI(47.6%对36.6%,P=0.003)均能区分中低危和中高危组患者,但前两者区分效果似乎更佳;而R-CHOP方案组,NCCN-IPI拥有更好的预后分层能力,其低危、中低危、中高危患者的5年OS率分别为96.0%、83.0%、66.5%(P=0.009)。③Harrell’s C分析结果显示,IPI、NCCN-IPI及aa-IPI预测接受CHOP方案者OS的一致性指数(C-index)分别为0.546、0.667、0.698;预测接受R-CHOP方案者OS的C-index分别为0.611、0.654、0.695。④在≤60岁患者中,IPI、NCCN-IPI、aa-IPI预测接受CHOP方案者OS的C-index分别为0.534、0.675、0.698;预测接受R-CHOP方案者OS的C-index分别为0.584、0.648、0.695。 结论: NCCN-IPI对于接受利妥昔单抗联合化疗的DLBCL患者有较好的预后分层能力,而aa-IPI对于较年轻的DLBCL患者预后分层能力可能更佳。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Song JL, Wei XL, Zhang YK, et al. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 30369184. doi:10.3760/cma.j.issn.0253-2727.2018.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。